Biotech | February 18, 2022
USFDA clears Kairos Pharma’s IND to treat prostrate cancer
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
The target demographic will be those between the ages of 30 and 65 years
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
Subscribe To Our Newsletter & Stay Updated
